article thumbnail

Reap What You Sow – UK’s Unallowable Purpose Rule Considered Again

JD Supra: Mergers

In Syngenta Holding Limited v HMRC [2024] UKFTT 998 (TC) (Syngenta), the UKs First-tier Tribunal (FTT) denied a deduction for interest on an intra-group loan on the basis that the loan had an unallowable purpose for the purposes of section 411 of the Corporation Tax Act 2009 (CTA 2009). By: Cadwalader, Wickersham & Taft LLP

article thumbnail

Healthcare & Life Sciences Private Equity Deal Tracker: Accel-KKR Acquires VisiQuate

JD Supra: Mergers

VisiQuate, founded in 2009 and based in Santa Rosa, California, is a provider of revenue cycle management and analytics solutions for health systems. Accel-KKR has acquired VisiQuate, according to a news release. By: McGuireWoods LLP

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The European Commission report on competition enforcement in the pharmaceutical sector

JD Supra: Mergers

The report looks at enforcement from 2018 - 2022 and is a follow-up of the previous report which covered 2009 - 2017. By: Hogan Lovells

article thumbnail

Healthcare & Life Sciences Private Equity Deal Tracker: GTCR Nears Deal for Caravel Autism Health

JD Supra: Mergers

Caravel Autism Health, founded in 2009 and based in Green Bay, Wisconsin, is a provider of in-home intensive, post-intensive, pre-intensive and diagnostic evaluation services to children with autism spectrum disorder. GTCR is expected to acquire Caravel Autism Health, according to industry reports. By: McGuireWoods LLP

article thumbnail

A Capital Blow for Deducting Management Expenses

JD Supra: Mergers

The decision also confirms that once a company has decided in principle to dispose of a capital asset, any professional fees incurred afterwards in pursuance of that sale are likely to be capital and not deductible under CTA 2009 s 1219, even if a purchaser for that asset has not yet been identified and a specific sale transaction has not yet.

Capital 165
article thumbnail

Antitrust & Competition Life Sciences Quarterly Update - Q2 2023

JD Supra: Mergers

The Federal Trade Commission (FTC) announced its attempt to block Amgen/Horizon, the first such challenge to a life science transaction since 2009, and issued a second request in Pfizer’s proposed $43 billion acquisition of Seagen. The second quarter saw significant enforcement and dealmaking in the life sciences space. By: Goodwin

Trading 130
article thumbnail

What is Merger and Acquisition?

Lake Country Advisors

Mergers and acquisitions (M&A) are key strategies in today’s business landscape, often dictating a company’s success and market position. Definition and Key Concepts While distinct in their mechanics and outcomes, merger and acquisition share the common goal of corporate growth and market expansion. What is a Merger?